Coronavirus vaccine: Germany approves first human trials

Coronavirus vaccine: Germany approves first human trials

Coronavirus vaccine: Germany approves first human trials

In the authorized first part of the clinical trial in Germany, 200 healthy volunteers aged between 18 and 55 years will be vaccinated, according to the Paul-Ehrlich-Institut.

The Oxford team has already developed a vaccine against Mers, another type of coronavirus, using the same approach - and that had promising results in clinical trials.

The permission for conducting human trials was given to a Mainz-based company BioNTech for its active substance, PEI announced.

The PEI also claimed that "further clinical trials of Covid-19 vaccine candidates will start in Germany in the next few months". The clinical trials of the vaccine are generally performed on animals before humans.

Moderna MRNA is also developing an mRNA-based vaccine for COVID-19 in collaboration with the Biomedical Advanced Research and Development Authority ("BARDA") in a phase I study.

This clinical trial will help the Chinese pharmaceutical company to know whether the vaccine will be successful in treating COVID-19 infected patients or not and whether it has any side effects on humans.

Germany's health minister Jens Spahn responded that a United States takeover of CureVac was "off the table", and that if CureVac made a vaccine it should be available for the world, not for individual countries.

"It's a good sign that the development of vaccines in Germany is at a stage at which we can begin with the first trials", Health Minister Jens Spahn said.

BioNTech, has assembled its teams in Germany, as it races others in the US and China to develop an agent that will help stop the pandemic.

"Protecting health and saving lives is at the forefront of our work, and we are committed to enabling the development of safe and effective vaccines and treatments for this virus". To combat the pandemic, additional vaccine products will be necessary to ensure a sufficient supply of the vaccines.

His startup is seeking over $100 million dollars in research funding and confirmed he plans to test the vaccine on himself next week. BioNTech stated that it was an improvement in the vaccine candidate, called BNT162, together with pharmaceutic giant Pfizer.

Related news



[an error occurred while processing the directive]